VivoSeq
Oncology

Early-Stage Breast Cancer

2

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

Early-stage Breast Cancer is an early-stage landscape with 2 programs across 3 companies. The most active players are Mario Negri Institute for Pharmacological Research, Sanofi, Ipsen. 2 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research

1 program

ApprovedSanofi logo

Sanofi

1 program

ApprovedIpsen logo

Ipsen

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved2

Zoledronate

Mario Negri Institute for Pharmacological Research

Granulocyte Colony-Stimulating Factor

Sanofi

Analysis

Trial Status

4

clinical trials

Completed2 · 50%
Withdrawn1 · 25%
Recruiting1 · 25%

Clinical Trials

Trial Activity

Noninterventional, Multicentre, Prospective, Cohort Study Assessing the Quality of Life and Hormonal Levels in Premenopausal Patients With Hormone Receptor-positive and HER2-negative Early Breast Cancer in Italy - ROSE Study
Completed·Ipsen logoIpsen·N/A·NCT05377684·450 enrolled
BAriaTric Surgery After Breast Cancer Treatment (BATS) - A Randomized Trial of Sleeve Gastrectomy Versus Lifestyle Intervention in Women Diagnosed With Early Stage Breast and With a BMI of ≥ 35
Withdrawn·MMasonic Cancer Center, University of Minnesota·Preclinical·NCT03946423
A Randomized Pragmatic Trial Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy (REaCT-OGF)
Recruiting·OOttawa Hospital Research Institute·Approved·NCT05753618·242 enrolled
A Randomised, Multicentre, Pragmatic Trial Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL)
Completed·OOttawa Hospital Research Institute·Approved·NCT03664687·211 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)